

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: **MS RCE**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: July 19, 2004

Signature:

Nabeela R. McMillian

Docket No.: 01017/39996  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of: John Sims

Application No.: 09/598,443

Group Art Unit: 1647

Filed: June 22, 2000

Examiner: Fozia M. Hamud

For: SIGIRR DNA AND POLYPEPTIDES

**INFORMATION DISCLOSURE STATEMENT (IDS)**

**MS RCE**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached Form PTO - 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

References C2 and C4 are submitted in their entirety, while only the abstracts of references C1 and C3 are submitted herewith. All of these references were published after the filing date of the instant application and therefore are not "prior art". These references are being submitted herewith in relation to a discussion of utility in a response that is filed concurrently herewith. The submission of this PTO-1449 and IDS is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for the instant application under any section of 35 U.S.C. §102 or 35 U.S.C. §103.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. It is submitted that the Information

Application No.: 09/598,443

Docket No.: 01017/39996

Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

No additional fees are believed to be necessary with the filing of this paper, however, the Commissioner is hereby authorized to charge any deficiency in the fees filed or credit any overpayments to our Deposit Account No. 13-2855. A duplicate copy of this paper is enclosed.

Dated: July 19, 2004

Respectfully submitted,

By 

Nabeela R. McMillian

Registration No.: 43,363

MARSHALL, GERSTEIN & BORUN LLP


233 S. Wacker Drive, Suite 6300

Sears Tower

Chicago, Illinois 60606-6357

(312) 474-6300

Attorney for Applicants



Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark Office

Attorney Docket No.

01017/39996

Serial No.

09/598,443

Applicant

John Sims

Filing Date

June 22, 2000

Group

1647

## INFORMATION DISCLOSURE STATEMENT

## U.S. PATENT DOCUMENTS

*Examiner Initials	Document Number	Issue Date	Name	Class	Subclass	Filing Date if Appropriate

## FOREIGN PATENT DOCUMENTS

*Examiner Initials	Document Number	Publication Date	Country	Class	Subclass	Translation Yes No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C1	Mantovani et al., J. Leukoc. Biol., 75(5):738-742 (2004) – (Abstract Only)
C2	O'Neill, Nature Immunol., 4(9):823-824 (2003)
C3	Polentarutti et al., Eur. Cytokine Netw., 14(4):211-218 (2003) – (Abstract Only)
C4	Wald et al., Nature Immunol., 4(9):920-927 (2003)

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.